Apart from the similar findings like lower serum leptin concentrations in ovarian cancer patients than controls (n=51), the investigators of a study also found that patients with stage III/IV (n=38) had lower mean serum leptin levels in comparison to patients with I/II stage (n=15) (Grabowski et al., 2014). This evidence concerns the gene LEP and ovarian cancer.